Corticosteroids as an Adjuvant Treatment to Surgery in Chronic Subdural Hematomas: A Multi-Center Double-Blind Randomized Placebo-Controlled Trial - Aix-Marseille Université Access content directly
Journal Articles Journal of Neurotrauma Year : 2021

Corticosteroids as an Adjuvant Treatment to Surgery in Chronic Subdural Hematomas: A Multi-Center Double-Blind Randomized Placebo-Controlled Trial

Sam Ng
Pascal Sabatier
  • Function : Author
Emilie Aloy
  • Function : Author
Guillaume Boniface
  • Function : Author
Emilie Chan-Seng
  • Function : Author
Jérôme Cochereau
  • Function : Author
Henry Dufour
  • Function : Author
Kaissar Farah
  • Function : Author
Denis Fontaine
  • Function : Author
Thomas Graillon
  • Function : Author
Guillaume Gras-Combe
  • Function : Author
Vanessa Gros
  • Function : Author
William Haynes
  • Function : Author
Kifah Khouri
  • Function : Author
Marine Le Corre
  • Function : Author
André Maillard
  • Function : Author
Philippe Paquis
  • Function : Author
Gaëtan Poulen
  • Function : Author
Adeline Quintard
  • Function : Author
Marie-Ange Rodriguez
  • Function : Author
Alice Rolland
  • Function : Author
Maxime Ros
  • Function : Author
François Segnarbieux
  • Function : Author
Nizar Suleiman
  • Function : Author
Lucas Troude
Matthieu Vassal
  • Function : Author
Anne-Sophie Verissimo
  • Function : Author

Abstract

Chronic subdural hematoma (CSDH) is a common condition necessitating surgery; however, recurrence occurs in 15–25% of cases despite surgical management. The HEMACORT trial was a prospective randomized, double-blind, placebo-controlled, multi-centric study (NCT01380028). The aim of this trial was to determine the effect of corticosteroids as an adjuvant treatment to surgery on CSDH recurrence at 6 months. After surgery, participants were assigned by block-randomization to receive either placebo or oral prednisone at a dose of 1 mg/kg/day followed by weekly stepwise tapering in steps of 10 mg/day. The primary outcome was CSDH recurrence, defined by the need for reoperation and/or radiological progression of CSDH. Secondary outcomes were one-year death, radiological changes, safety, neurological status, and quality of life. The trial was discontinued at midpoint of expected inclusions: 78 participants received prednisone and 77 received placebo controls. In an intention-to-treat analysis, CSDH clinicoradiological recurrence was not different between prednisone and placebo groups (21.8% vs. 35.1%, respectively; hazard ratio 0.56; 95% confidence interval 0.30–1.02; p = 0.06), although post hoc analyses concluded to statistical significance (p = 0.02). Earlier radiological resolution was observed after prednisone administration, but reoperation rates (reaching 5.8% overall) and functional outcomes were not different at 6 months. Among adverse events, sleep disorders occurred more often in the prednisone group (26.1% vs. 9.1%, p = 0.02). The HEMACORT trial data suggest that prednisone, as an adjuvant treatment to surgery, may reduce early radiological recurrence of CSDH, although clinical benefits are unclear. In view of these findings, the authors suggest that shorter treatment duration should be assessed for safety and efficacy in future trials.
Fichier principal
Vignette du fichier
neu.2020.7560.pdf (769.21 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-03574895 , version 1 (04-05-2022)

Identifiers

Cite

Sam Ng, Julien Boetto, Héléna Huguet, Pierre-Hugues Roche, Stéphane Fuentes, et al.. Corticosteroids as an Adjuvant Treatment to Surgery in Chronic Subdural Hematomas: A Multi-Center Double-Blind Randomized Placebo-Controlled Trial. Journal of Neurotrauma, 2021, 38 (11), pp.1484-1494. ⟨10.1089/neu.2020.7560⟩. ⟨hal-03574895⟩
108 View
107 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More